Trial · NCT07893834
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
NCT07893834, Not applicable, Not yet recruiting, Tampere University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections. Trials, record NCT07893834. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893834
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
- NCT number
- NCT07893834
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50,000 participants, estimated
- Lead sponsor
- Tampere University
- Conditions
- Bronchitis, Acute, Community-acquired Pneumonia, Respiratory Tract Infections
- Interventions
- PRACTICE-LRTI multimodal antimicrobial stewardship programme
- First posted
- 2026-10-26
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of acute bronchitis episodes with a systemic antibiotic prescription | Month 36 after programme launch | Proportion of eligible acute bronchitis episodes (index visit plus related visits within 14 days for the same child) with at least one systemic antibiotic prescription, measured in Month 36 after programme launch (end of Step 3). Unit of measure: percentage of episodes. The intervention effect is reported as the absolute difference in percentage points, with 95% confidence interval, between the observed proportion and the counterfactual proportion projected from the pre-launch monthly series (published 2014 to 2020 series extended month by month to the month before launch), estimated by segmented binomial regression. Target: below 15% (minimum acceptable below 20%) from a baseline of 32%. |
| Primary | Proportion of antibiotic-treated outpatient community-acquired pneumonia episodes with a non-first-line antibiotic | Month 36 after programme launch | Proportion of antibiotic-treated outpatient community-acquired pneumonia (CAP) episodes in which a non-first-line agent is prescribed, defined as any systemic antibiotic other than amoxicillin (ATC J01CA04); the non-first-line share is the complement of the amoxicillin share, measured in Month 36 after programme launch (end of Step 3). Unit of measure: percentage of antibiotic-treated CAP episodes. The intervention effect is reported as the absolute difference in percentage points, with 95% confidence interval, between the observed proportion and the counterfactual proportion projected from the pre-launch monthly series, estimated by segmented binomial regression. Corresponds to the target of increasing first-line amoxicillin from 65% to above 80% of antibiotic-treated CAP. |
| Secondary | Proportion of acute bronchitis episodes with a systemic antibiotic prescription at Month 12 | Month 12 after programme launch | Same measurement and analysis as the first co-primary outcome, assessed in Month 12 after programme launch (end of Step 1). Unit of measure: percentage of episodes; effect reported as the absolute difference in percentage points from the counterfactual, with 95% confidence interval. |
| Secondary | Proportion of acute bronchitis episodes with a systemic antibiotic prescription at Month 48 | Month 48 after programme launch | Same measurement and analysis as the first co-primary outcome, assessed in Month 48 after programme launch (end of the 1-year follow-up without new active intervention), as the measure of durability. Unit of measure: percentage of episodes; effect reported as the absolute difference in percentage points from the counterfactual, with 95% confidence interval. |
| Secondary | Proportion of antibiotic-treated outpatient community-acquired pneumonia episodes with a non-first-line antibiotic at Month 12 | Month 12 after programme launch | Same measurement and analysis as the second co-primary outcome, assessed in Month 12 after programme launch (end of Step 1). Unit of measure: percentage of antibiotic-treated CAP episodes; effect reported as the absolute difference in percentage points from the counterfactual, with 95% confidence interval. |
| Secondary | Proportion of antibiotic-treated outpatient community-acquired pneumonia episodes with a non-first-line antibiotic at Month 48 | Month 48 after programme launch | Same measurement and analysis as the second co-primary outcome, assessed in Month 48 after programme launch (end of the 1-year follow-up), as the measure of durability. Unit of measure: percentage of antibiotic-treated CAP episodes; effect reported as the absolute difference in percentage points from the counterfactual, with 95% confidence interval. |
| Secondary | Proportion of antibiotic-treated outpatient community-acquired pneumonia episodes treated with amoxicillin | Month 36 after programme launch | Proportion of antibiotic-treated outpatient CAP episodes in which amoxicillin (ATC J01CA04) is the prescribed antibiotic, measured in Month 36 after programme launch. Unit of measure: percentage of antibiotic-treated CAP episodes. Analysed by segmented regression against the pre-launch counterfactual. Target: above 80%. |
| Secondary | Proportion of antibiotic-treated outpatient community-acquired pneumonia episodes with a macrolide prescription | Month 36 after programme launch | Proportion of antibiotic-treated outpatient CAP episodes in which a macrolide (ATC J01FA) is prescribed, measured in Month 36 after programme launch. Unit of measure: percentage of antibiotic-treated CAP episodes. Analysed by segmented regression against the pre-launch counterfactual. Target: below 10%. |
| Secondary | Proportion of acute bronchitis episodes with a macrolide prescription | Month 36 after programme launch | Proportion of eligible acute bronchitis episodes in which a macrolide (ATC J01FA) is prescribed, measured in Month 36 after programme launch. Unit of measure: percentage of episodes. Analysed by segmented regression against the pre-launch counterfactual. |
| Secondary | Proportion of community-acquired pneumonia amoxicillin courses with a prescribed duration of 5 days or less | Month 36 after programme launch | Proportion of amoxicillin courses prescribed for outpatient CAP with a prescribed duration of 5 days or less (guideline-concordant duration), measured in Month 36 after programme launch. Unit of measure: percentage of CAP amoxicillin courses. Analysed by segmented regression against the pre-launch counterfactual. Target: above 50%. |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893834
GET https://conductscience.org/api/trials/v1/NCT07893834/registered?page=2